An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Phase 3
280
about 4 years
18–65
79 sites in AR, AZ, CA +20
About this study
Researchers are testing the safety and tolerability of a treatment called KarXT, which contains xanomeline and trospium chloride, for people with schizophrenia who haven't responded well to their current medication. The trial will last 1473 days and involve about 280 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Xanomeline and Trospium Chloride Capsules
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
trospium, Antipsychotic Agent [TC] (Cholinergic Muscarinic Agonists)
oral
Primary: Incidence of treatment-emergent adverse events (TEAEs)
Secondary: Incidence of TEAEs leading to discontinuation of study drug, Incidence of serious treatment-emergent adverse events (TEAEs)
Psychiatry / Mental Health